Alumis Inc. Common Stock (ALMS) NASDAQ
25.06
-0.32(-1.26%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
25.06
-0.32(-1.26%)
Currency In USD
| Previous Close | 25.38 |
| Open | 24.75 |
| Day High | 25.26 |
| Day Low | 24 |
| 52-Week High | 30.6 |
| 52-Week Low | 2.76 |
| Volume | 3.88M |
| Average Volume | 2.97M |
| Market Cap | 2.62B |
| PE | -11.66 |
| EPS | -2.15 |
| Moving Average 50 Days | 25.85 |
| Moving Average 200 Days | 10.42 |
| Change | -0.32 |
Alumis to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler,
Alumis to Participate in Upcoming February Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company wil
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 09, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the clos